企業プロフィール · Industrials

FUJIFILM Holdings Corp

4901 · TSE
取引所
TSE
国 / 地域
USA
上場日
1949年5月1日
従業員数
72,593
公式サイト
holdings.fujifilm.com
現在値
¥3,436
2026年6月28日 終値
妥当買付価格
≤ ¥2,650
安全マージンの起点
ベイリー成長スコア
46/100
やや弱い
本源的価値 · 3 段階レンジ 現在値 ¥3,436 · 妥当な本源的価値レンジ内

総合バリュエーションレンジ · 保守的 ¥2,450–¥2,650 / 妥当 ¥3,250–¥4,150 / 楽観的 ¥5,150–¥5,450。¥3,436 時点で 妥当な本源的価値レンジ内。

2026年5月20日 Update Confirmed

FUJIFILM Cellular Dynamics Launches New iPSC Manufacturing Facility in Madison

FUJIFILM Cellular Dynamics opened a new Madison iPSC headquarters and manufacturing facility, part of a $200 million U.S. investment.

Possible impact:May affect expectations for cell therapy manufacturing and life-sciences growth.

FUJIFILM CorporationView source
2026年5月12日 Earnings Confirmed

Fujifilm Announces Financial Results for the Fiscal Year Ended March 31, 2026

Fujifilm reported record FY2026 revenue, operating income and net income, and guided for further growth in FY2027.

Possible impact:May affect expectations for sustained growth in healthcare, semiconductor materials and imaging.

FUJIFILM Holdings CorporationView source
2026年5月8日 Regulatory Confirmed

Fujifilm Announces Approval of SAVYSCUS Injection in Japan

FUJIFILM Toyama Chemical received Japanese approval for SAVYSCUS Injection, a regenerative medical product for meniscal injury.

Possible impact:May affect expectations for regenerative medicine commercialization and healthcare differentiation.

FUJIFILM CorporationView source
2026年4月23日 Product Confirmed

Fujifilm Develops the World’s First Fluorine-Free Negative ArF Immersion Resist

Fujifilm developed a fluorine-free negative ArF immersion photoresist for advanced AI semiconductor nodes and began sampling.

Possible impact:May affect expectations for semiconductor materials competitiveness and PFAS-replacement demand.

FUJIFILM CorporationView source
2026年3月12日 Financing Confirmed

Fujifilm Invests in VALANX Biotech to Strengthen ADC CDMO Capabilities

Fujifilm invested in Austria’s VALANX Biotech to strengthen ADC CDMO technology and manufacturing capabilities.

Possible impact:May affect expectations for Bio CDMO positioning in the fast-growing ADC market.

FUJIFILM CorporationView source

Automatically summarized from public sources; for context only, not investment advice.

時価総額$252.07億
売上高(TTM)$3.36兆
EBITDA$5225.81億
純利益率8.24%
ROE7.71%
PER (TTM)15.04
予想PER13.21
PEG2.21
EPS$0.70
配当利回り2.22%
52週レンジ$8.82 – $12.09

データ提供:EODHD、報告通貨で表示。参考情報であり、投資助言ではありません。

FUJIFILM Holdings Corporation provides products and services in the fields of healthcare, electronics, business innovation, and imaging in Japan, the Americas, Europe, Asia, and internationally. The Healthcare segment offers products and services, such as medical devices, biomedical contract development and manufacturing organization, pharmaceutical, regenerative medicine, and cosmetics and supplements in the areas of prevention, diagnosis, and treatment; equipment and materials for medical systems; drug discovery support, such as iPS cells; and cell culture media and reagents. Its Electronic segment provides display and touch panel, semiconductor and image sensors, and functional film materials; storage media and archiving services; semiconductor and display materials; industrial equipment; and fine chemicals. The Business Innovation segment offers office equipment, including multi-function devices and printers; problem-solving document services tailored to diverse business formats and roles, including system integration, cloud service, business process outsourcing, and others; equipment and materials for graphic communications; and inks and industrial inkjet printheads. Its Imaging segment provides color films, instant cameras, developing and printing systems, color papers, and photo printing services; TV and cinema lenses, surveillance cameras, industrial lenses for production line inspection, and projectors; instant photo systems; services for photofinishing; digital cameras; and optical devices. FUJIFILM Holdings Corporation was incorporated in 1934 and is headquartered in Minato, Japan.

沿革

近日公開このセクションは現在準備中です。近日公開予定です。

業界での地位

近日公開このセクションは現在準備中です。近日公開予定です。

この銘柄のレポートはお使いの言語でまだありません。